XenoPort Announces New Employment Inducement Award Business Wire SANTA CLARA, Calif. -- December 07, 2012 XenoPort, Inc. (Nasdaq: XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Richard Galvez, was granted restricted stock units representing an aggregate of 1,000 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the December 3, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort’s board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4). About XenoPort XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant^® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights for Horizant in the United States during a transition period ending on April 30, 2013, following which XenoPort will be responsible for the further development, manufacturing and commercialization of Horizant. Regnite^® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort’s pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis. To learn more about XenoPort, please visit the Website at www.XenoPort.com. XENOPORT, Horizant and Regnite are registered trademarks of XenoPort, Inc. XNPT2G Contact: XenoPort, Inc. Jackie Cossmon, 408-616-7220 ir@XenoPort.com
XenoPort Announces New Employment Inducement Award
Press spacebar to pause and continue. Press esc to stop.